JAK1 and COVID-19: In the scenario of late severe COVID-19, in which the accumulation of IMMs in the lungs as the main source of pro-inflammatory cytokines is associated with fatal disease, targeted antagonism of the JAK pathway with JAKinhibs such as baricitinib (Olumiant®)—a dual JAK1/JAK2 inhibitor approved by the European Medicines Agency for moderate-to-severe active rheumatoid arthritis in adults [79,80,81,82]—would improve outcomes given their non-selective capacity to inhibit cytokine release and block cytokine signaling.